Navigation Links
Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001,at American Association of Cancer Research Annual Meeting

CAMBRIDGE, Mass., April 13, 2007 /PRNewswire/ -- Mersana, a cancer therapeutics company, announced today that results of preclinical studies with its lead product candidate, XMT-1001, will be presented in two posters at the 2007 Annual Meeting of the American Association of Cancer Research (AACR) taking place April 14-18th in Los Angeles, CA. Full text of the abstracts can be viewed online at the AACR website at http://www.AACR.org.

The presentation schedule is as follows:

Abstract #781 "XMT-1001, a novel polymeric prodrug of camptothecin, is a potent inhibitor of LS174 and A2780 human tumor xenografts in a mouse model" will be presented in a poster session on Sunday, April 15th from 8:00 am - 12:00 pm. Alex Yurkovetskiy and Russell C. Petter are the presenting authors.

Abstract #4723 "Pharmacokinetics of a novel camptothecin conjugate (XMT- 1001) in the rat and dog" will be presented in a poster session on Tuesday, April 17th from 1:00 - 5:00 pm. Ullrich Schwertschlag and Alex Yurkovetskiy are the presenting authors.

About XMT-1101

XMT-1001 is Mersana's most advanced Fleximer(R)-based product candidate. It utilizes a novel, dual release mechanism to liberate a camptothecin prodrug, which is then converted within cells into camptothecin, a DNA topoisomerase I inhibitor. In preclinical studies, XMT-1001 was better tolerated and more efficacious than either camptothecin or irinotecan in models of human cancer, showing extended plasma half-life and high concentrations in tumor tissue.

About Fleximer Technology

Fleximer(R) technology improves the therapeutic index of cytotoxic compounds useful as anti-cancer agents by uniquely combining biodegradability with "biological stealth" properties, making Fleximer(R) materials and their conjugates long-circulating and non-immunotoxic. Fleximer(R) molecules are characterized
'"/>




Page: 1 2

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. The Past, Present and Future of HLA Typing
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
(Date:12/4/2009)..., INDIANAPOLIS, Dec. 4 /PRNewswire-FirstCall/ -...day approved Zyprexa® (olanzapine) in tablet ...ia and manic or mixed episodes associated with bip...d. ,, The updated Zyprexa label states that cl...sed potential for weight gain and hyperlipidemia i...
(Date:12/4/2009)...OMAHA, Neb., Dec. 4 Amber Pharmacy... the Accreditation Commission for Health Care, Inc...arly 15 years, Amber Pharmacy has provided compreh... the unique needs of specialized conditions. Amber...ces to transplant programs. They work with over 17...
(Date:12/4/2009)... STREAMWOOD, Ill., Dec. 4 Shared I...d PET/CT systems and service programs for hospital... it has received The Joint Commission,s Accreditat...nized, prestigious gold seal of approval for quali...editation is system-wide for its mobile MRI and PE...
Breaking Medicine Technology:FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Amber Pharmacy Earns Accreditation From ACHC 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2Research and legislation should go hand in hand as much as possible 10861 1Research and legislation should go hand in hand as much as possible 10861 2Sporicidin Brand Disinfectant Kills H1N1 in 3 Minutes 14943 1Sporicidin Brand Disinfectant Kills H1N1 in 3 Minutes 14943 2Milwaukee Employers See Cost Savings with High Performance Provider Network 61921 1Milwaukee Employers See Cost Savings with High Performance Provider Network 61921 2
...mmunity Hospital to Offer New Clinical Study to Br...EVERGREEN PARK, Ill., Jan. 29 Little Company of M...Park, Illinois, near Chicago,( http://www.Pursuing...t will,offer a new clinical study by Xoft using el...stage breast cancer. The study involves the delive...
...a Posted Online Shows Improvements Across Care Cen...ibrosis,Foundation reported today that key indicat...ncluding lung function and nutritional status -- a...nter network., In fact, the outlook for people wi...nd this progress is accelerating due to quality im...
Other Medicine Technology:Breast Cancer Treatment Is Reduced to One Week 2Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes 2
(Date:12/4/2009)...ire-FirstCall/ -- Care Investment Trust Inc. (NY...ced that its Board of Directors has declared a div...idend is payable on December 22, 2009 to common sh..., About Care Investment Trust ,, Care Investm...ance company investing in healthcare-related real ...
(Date:12/4/2009)... Dec. 4 Allied World Ass...announced that Scott Carmilani,President and Chie...ice,President and Chief Corporate Strategy Officer.... Financial Services Conference being held at the ...n Tuesday, December 8, 2009. ,, About All...
(Date:12/4/2009)...4 The large, two-day free health c...e Clinics (NAFC) in Kansas City on Wednesday and T...ne who is uninsured and has not seen a doctor rece...eceive preventive primary care. ,, "Many peopl...c events this fall in Houston, New Orleans and Lit...
(Date:12/4/2009)...Newswire-USNewswire/ -- While Congress debates whe...costs, Leapfrog,s purchaser members point to 45 ho...e best quality care in the nation while attaining ...n, eight children,s and three rural hospitals have...results from The Leapfrog Hospital Survey. ,, ...
(Date:12/4/2009)...udy shows that muscle cells grown in the lab can r...erly. The work, performed in dogs and rats, might ...h as gastric reflux and fecal incontinence. , Th... which are the bands of muscle that separate the m...n these areas can cause gastrointestinal esophagea...
Breaking Medicine News(10 mins):Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4
...in association with fellow researchers from the Ma...out the shape function //and structure of the prot... with great accuracy and studied its interaction w...d Molecular Biology.Calbindin-D28K is a protein th...
...s, Ph.D. and Helain Landy, M.D. of Georgetown Univ...various methods of family //planning while they ar... the Contemporary Obstetrics & Gynecology journal ...an appropriate contraceptive method. ‘Ideally a ph...
...nded applicants, with at least one year’s work exp...pier doctors, suggests a leading// educationalist ... Dr Christopher Cowley, of the School of Medicine...r in medicine. He contends that these would ...
...ee doctors to an HIV-positive patient in a governm...(JDA) has said its members// would not perform any...ct them from the disease. "The JDA is of th...e future," Madhya Pradesh JDA general secretary An...
...rgery was successfully performed on an eight-month...ere.// Ebtisam Ibrahim was initially evaluat...er Lifeline Hospital and was diagnosed to have com...age in the valves, Madhu Sankar, a heart surgeon o...
...Kingdom has initiated a two-year study to measure ...dren's experience with respect to// schooling, edu...have an indelible impact on childhood, will be stu...eier, chief executive of the Children's Society, s...
Other Medicine News:Health News:Scientists Unravel the Mystery behind Calbindin-D28K Protein 2Health News:Gap Exists between Medical School Teaching and Physician’s Practic 2Health News:Older, More Rounded, and Artier Applicants make Better Medical Students 2
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
Medicine Products: